Opdivo (Nivolumab)

Nivolumab, the active ingredient in Opdivo, is a PD‑1 inhibitor presented as a sterile solution for subcutaneous use. It is employed in cancer immunotherapy to enhance the immune system’s ability to target tumor cells in adult patients with specific malignancies.

GNH USA supplies Opdivo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Opdivo acts on the programmed death‑1 pathway and is indicated for several advanced cancers.

- Melanoma: improves overall survival in patients with unresectable or metastatic disease. - Non‑small cell lung cancer: used as first‑line or subsequent therapy for advanced disease. - Renal cell carcinoma: extends progression‑free survival in metastatic cases. - Classical Hodgkin lymphoma: provides durable responses in relapsed or refractory patients. - Head and neck squamous cell carcinoma: enhances response rates when combined with chemotherapy. - Urothelial carcinoma: offers treatment option for locally advanced or metastatic disease.

Adverse reactions to Opdivo can range from mild to severe and are related to immune system activation.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Rash: skin eruptions that may be itchy or painful. - Pruritus: generalized itching without visible rash. - Diarrhea: loose stools that may lead to dehydration. - Nausea: sensation of unease and urge to vomit. - Infusion‑related reactions: flushing, chills, or fever during administration.

Serious or Rare Side Effects: - Pneumonitis: inflammation of lung tissue that can impair breathing. - Colitis: severe inflammation of the colon causing abdominal pain and diarrhea. - Hepatitis: liver inflammation leading to elevated enzymes. - Endocrinopathies: dysfunction of thyroid, pituitary, or adrenal glands. - Nephritis: kidney inflammation potentially reducing renal function. - Severe infusion reactions: anaphylaxis or hypotension requiring emergency care.

Before initiating Opdivo, clinicians should consider several safety measures.

- Monitor for immune‑related adverse events: watch for signs of organ inflammation such as cough, diarrhea, or jaundice. - Assess baseline organ function: perform liver, kidney, and thyroid tests prior to treatment. - Avoid use in patients with active uncontrolled infections: postpone therapy until infection is resolved. - Consider vaccination status: live vaccines are contraindicated during treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Opdivo may interact with other therapies that influence immune function.

Major Interactions (Avoid): - Concurrent high‑dose systemic steroids: may diminish therapeutic efficacy. - Organ transplantation: increased risk of graft rejection due to immune activation. - Other immune checkpoint inhibitors: combined use can amplify toxicity. - Live vaccines: can cause uncontrolled infection.

Moderate Interactions (Monitor Closely): - Cytotoxic chemotherapy: may increase hematologic toxicity. - Targeted therapies (e.g., tyrosine kinase inhibitors): potential overlapping adverse effects. - Anticoagulants: monitor for bleeding if immune‑related thrombocytopenia occurs.